- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07837674
Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine
The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Study Overview
Status
Intervention / Treatment
Detailed Description
Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.
Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.
Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.
This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julie Desroches, PhD
- Phone Number: 24542 514-890-8000
- Email: anesthesie.recherche.chum@ssss.gouv.qc.ca
Study Contact Backup
- Name: Stephan Williams, MD, PhD
- Phone Number: 12132 514-890-8000
- Email: stephan.williams@umontreal.ca
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- Santé Québec - Centre hospitalier de l'Université de Montréal
-
Contact:
- Julie Desroches, PhD
- Phone Number: 24542 514-890-8000
- Email: anesthesie.recherche.chum@ssss.gouv.qc.ca
-
Contact:
- Stephan Williams, MD, PhD
- Phone Number: 12132 514-890-8000
- Email: stephan.williams@umontreal.ca
-
Principal Investigator:
- Stephan Williams, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 90 years old
- ASA status I to III inclusively
- Planned lower body surgery under spinal anesthesia with chloroprocaine
- Signed informed consent form
Exclusion Criteria:
- Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
- Preexisting neuropathy or nerve block that could interfere with study assessments
- Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
- Preoperative use of corticosteroids
- Patient refusal
- Inability to consent
- Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
- Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
- Perioperative intravenous dexmedetomidine administration
- Conversion to general anesthesia
- Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
- Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intravenous dexamethasone
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine
Other Names:
|
|
Placebo Comparator: Intravenous normal saline
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Regression of sensory block by 2 dermatomes
Time Frame: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level |
At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of motor block
Time Frame: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Time until the first observable regression of the motor block
Time Frame: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale. |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Onset of sensory block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation |
Up to 30 minutes following spinal anesthesia
|
|
Onset of motor block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale |
Up to 30 minutes following spinal anesthesia
|
|
Quality of motor block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block. The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block. |
Up to 30 minutes following spinal anesthesia
|
|
Opioid consumption
Time Frame: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of opioids |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Antiemetic consumption
Time Frame: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of antiemetics |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Incidence of hypotension
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Systolic blood pressure lower than 90 mm Hg |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of bradycardia
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Heart rate slower than 50 beats per minute |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of nausea
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of nausea reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of vomiting
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of retching or vomiting reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of itching
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of itching reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of urinary retention
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of urinary retention reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of shivering
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of shivering reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of headache
Time Frame: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of headache reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Quality of postoperative recovery
Time Frame: At 24 hours after the surgery
|
QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome). |
At 24 hours after the surgery
|
|
Intensity of nausea/vomiting
Time Frame: At 24 hours after surgery
|
Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Pain intensity
Time Frame: At 24 hours after surgery
|
Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Quality of sleep
Time Frame: At 24 hours after surgery
|
Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Surgeon's satisfaction towards spinal anesthesia
Time Frame: At the end of surgery, on the day of randomization
|
Unsatisfied or satisfied |
At the end of surgery, on the day of randomization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephan Williams, MD, PhD, Santé Québec - CHUM
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Sulfur Compounds
- Organic Chemicals
- Pharmaceutical Preparations
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Benzene Derivatives
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Sulfonic Acids
- Sulfur Acids
- Benzenesulfonates
- Arylsulfonates
- Arylsulfonic Acids
- Calcium Dobesilate
- Saline Solution
Other Study ID Numbers
- 2027-13916
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.